- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Olanzapine, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 1,349
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease
- Interventions
- Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
- Drug
- Lead sponsor
- Baim Institute for Clinical Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 178
- States / cities
- Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
- Conditions
- Osteoarthritis
- Interventions
- LY3556050, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 32 more
- Conditions
- Procedural Skill Competency
- Interventions
- Competency based simulation training
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- Not listed
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Ovarian Cancer Recurrent
- Interventions
- Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 10
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
- Interventions
- TALZENNA capsule, Talazoparib soft gel capsule
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 23
- States / cities
- Encinitas, California • Los Angeles, California • San Marcos, California + 12 more
- Conditions
- Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
- Interventions
- Palifermin
- Drug
- Lead sponsor
- Brett King
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Bridgeport, Connecticut • New Haven, Connecticut
- Conditions
- Critical Limb Ischemia
- Interventions
- Oxygenesys(TM) Dissolved Oxygen Dressing
- Device
- Lead sponsor
- Halyard Health
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Suicide, Attempted
- Interventions
- DBT-SG, VHA treatment as usual
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- San Diego, California • West Haven, Connecticut • Tampa, Florida + 2 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 105
- States / cities
- Fremont, California • Los Angeles, California • San Francisco, California + 37 more
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more
- Conditions
- Internal Carotid Artery Stenosis, Cognitive Impairment
- Interventions
- Revascularization, Intensive Medical Management (IMM) alone
- Procedure · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 35 Years to 86 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
- Conditions
- Urothelial Cancer
- Interventions
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Pain
- Interventions
- Valveless recirculating insufflation (VTI), Conventional pressure
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pediatric Crohn's Disease
- Interventions
- Methotrexate, Sugar pill (placebo)
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
- Conditions
- Enteral Feeding, Nutrition Disorders
- Interventions
- Intermittent feed participant, Continuous feeds participant
- Dietary Supplement
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
- Interventions
- Zilver Vena Venous Self-Expanding Stent
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Littleton, Colorado + 24 more
- Conditions
- Healthy, Informed Consent
- Interventions
- Not listed
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 836 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2008
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • No. Little Rock, Arkansas • Loma Linda, California + 19 more
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Interventions
- tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 124
- States / cities
- Encinitas, California • La Jolla, California • Sacramento, California + 57 more
- Conditions
- Atrial Fibrillation, Mitral Valve Insufficiency, Mitral Valve Stenosis
- Interventions
- MVS, Ablation
- Procedure · Device
- Lead sponsor
- Annetine Gelijns
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 18
- States / cities
- New Haven, Connecticut • Newark, Delaware • Atlanta, Georgia + 14 more
- Conditions
- Advanced Solid Tumor, Recurrent Glioma
- Interventions
- PRT811
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Denver, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
- Conditions
- Systolic Heart Failure, Respiratory Failure
- Interventions
- Airvo 3
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp alfa, Dexamethasone
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 27
- States / cities
- Springdale, Arkansas • Glendale, California • Orange, California + 23 more
- Conditions
- Hemophilia A
- Interventions
- PF-05280602
- Biological
- Lead sponsor
- Catalyst Biosciences
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 9
- States / cities
- San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more